论文部分内容阅读
目的:观察不同分期慢性肾脏病(CKD)患者血浆中P-选择素(CD62P)及细胞间黏附分子-1(ICAM-1)浓度,探讨其与肾功能损害的关系。方法:选取2008年本科收治住院的CKD患者80例,其中男47例,女33例,平均年龄(40.8±17.6)岁。所有患者均经病理诊断或临床确诊,且均符合CKD的诊断标准,并选取30例健康志愿者作为对照。血浆中CD62P、ICAM-1浓度采用流式细胞术及免疫技术检测。结果:CKD患者血浆中CD62P浓度(25.6±9.18)%、ICAM-1浓度(15.78±3.64)%明显高于正常人水平[(8.65±2.42)%和(5.46±1.67)%](均P<0.05)。随患者肾功能损害程度加重,血浆中CD62P、ICAM-1水平又呈逐渐下降趋势,且其浓度与CKD分期呈明显负相关(r=-0.6693、r=-0.7885,均P<0.01)。结论:血浆中CD62P及ICAM-1水平可反映并可作为CKD患者肾功能损害的重要指标,对指导临床诊疗工作具有重要意义。
Objective: To observe the plasma concentration of P-selectin (CD62P) and intercellular adhesion molecule-1 (ICAM-1) in patients with different stages of chronic kidney disease (CKD), and to explore its relationship with renal dysfunction. Methods: Eighty patients with CKD were admitted to our hospital in 2008, including 47 males and 33 females, with an average age of (40.8 ± 17.6) years. All patients were pathologically diagnosed or clinically diagnosed, and all meet the diagnostic criteria of CKD, and selected 30 healthy volunteers as a control. Plasma concentrations of CD62P and ICAM-1 were detected by flow cytometry and immunoassay. Results: The plasma concentrations of CD62P and ICAM-1 in CKD patients were significantly higher than those in healthy controls [(8.65 ± 2.42)% vs (5.46 ± 1.67)% vs (12.56 ± 9.18)%, P < 0.05). The levels of CD62P and ICAM-1 in plasma showed a tendency of decreasing with the aggravation of renal function. The concentration of CD62P and ICAM-1 in plasma showed a negative correlation with CKD stage (r = -0.6693, r = -0.7885, all P <0.01). Conclusion: The levels of CD62P and ICAM-1 in plasma can be reflected and can be used as an important index of renal dysfunction in patients with CKD, which is of great significance in guiding clinical diagnosis and treatment.